Irving, Texas (PRWEB) September 25, 2013
Findings from seven research studies conducted by the Miraca Life Sciences Research Institute have been selected for presentation at this year’s American College of Gastroenterology annual scientific meeting. Beginning Sunday, October 13, 2013 through Tuesday, October 15, attendees at the San Diego-based meeting will have an opportunity to review these seven studies, and learn about the specific clinical utility of these investigations to benefit patient care.
Dr. Robert M. Genta, Chief of Academic Affairs at the Miraca Life Sciences Research Institute and a Clinical Professor of Pathology and Gastroenterology at the University of Texas Southwestern Medical Center at Dallas, noted that the studies are based upon data from the company’s extensive repository of histopathologic, demographic and clinical patient information and represent important advancements in patient care.
Dr. Genta said, “With more than 5 million patients in our database, each complete with demographic, endoscopic, and clinical data, we are in a unique position to carry out nation-wide clinicopathologic research projects. The studies reported at this year’s meeting, as well as some studies recently published by Miraca Life Sciences pathologists, are prime examples of the broad cross-section of demographics and disease states that can lie at the foundation of our research endeavors.”
The seven studies by pathologists at Miraca Life Sciences include new insights suggesting that Eosinophilic Esophagitis and inflammatory bowel disease (IBD) may share a common immunopathogenetic mechanism; how the role of HIV infection and CD4 cells affect gastric mucosal response; and strong data supporting the assertion that Helicobacter-negative Chronic Active Gastritis occurs as a distinct condition, unrelated to H. pylori infection.
Another study confirmed the inverse relationship between Eosinophilic Esophagitis (EoE) and H. pylori infection (previously reported by Lash and Genta from Miraca Life Sciences in collaboration with researcher from the University of North Carolina) and expanded the observations to other conditions of the stomach, including autoimmune atrophic gastritis.
The Miraca Research Institute efforts, Dr. Genta says, “address diverse gastroenterological conditions that have widespread prevalence and incur significant burden to an individual’s quality of life, and expense to our health system.”
“It is imperative to develop new approaches in diagnosis and therapy. These can best develop from research that examines large amounts of data for nuances of pathologic relationships that would be undiscoverable in small studies, giving us insights to advance quality care and treatment outcomes in these populations.”
Also to be presented are conclusions from the largest clinicopathologic series of patients with documented spirochetosis, which found that the condition may be asymptomatic in more than half of the subjects infected. Researchers will also discuss the unexpected finding of fungal esophagitis in patients with endoscopically unremarkable esophagus, and how patients with diarrhea and microscopic colitis (MC) have a significantly lower prevalence of colorectal polyps, suggesting inhibition of epithelial proliferation by regulatory T-cells.
About Miraca Life Sciences
Serving more than 3,500 patients each day, Miraca Life Sciences is a leader in providing an academic-caliber pathology laboratory with diagnostic services in the fields of dermatology, gastroenterology, hematology and urology. Building upon our experience with health IT, we also offer accessible technology solutions to assist healthcare professionals as they work towards accordance with Meaningful Use initiatives.
Miraca Life Sciences, a wholly-owned subsidiary of Japan-based Miraca Holdings Inc., employs a talented team of leading pathologists, histologists, lab technicians, technology consultants, and other medical professionals — all driven to help provide the highest and most up-to-date levels of diagnostic quality, enhanced workflow and practice solutions possible. It is part of our commitment: not only to scientific excellence, but to patients and practices.